OM-210126-1535_temp_ | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.

A practical guide for Primary Care: Putting the CREDENCE data into practice for the management of Diabetic Kidney Disease (DKD) in people with T2DM

Join us for our upcoming promotional webcast series taking place in March and April 2021

Next event starting shortly. Already registered?

Join us for our upcoming promotional webcast series taking place in March and April 2021

Diabetic Kidney Disease (DKD) is primarily responsible for increased mortality in Type 2 diabetes.1 However, there have been no new treatments for DKD in nearly two decades.2,3

CREDENCE was the first SGLT2 inhibitor trial to assess renal-specific primary outcomes and it was ended early as efficacy and renal benefit were proved after only 2.6 years.4

Evidence was provided for SGLT2 inhibitors in reducing the risk of dialysis, transplantation, or death due to kidney disease in individuals with type 2 diabetes and protection against acute kidney injury5.

This series of webcasts will explore the rationale for identifying and treating DKD and provide a detailed overview of the CREDENCE trial results.

Each speaker will provide their analysis of SGLT2 inhibitors in relation to the renal effects and use data from the CREDENCE trial to clarify their perspective. The speakers will also be available to provide answers to any questions from the audience in a 20-minute live Q&A session at the end of every video presentation.

By the end of this series of webcasts you should understand the importance of detecting and preventing or slowing the progression of DKD, as well as the practical implications of CREDENCE on the management of DKD in primary care.

Registration allows you to attend all four webcasts in this series.

Upcoming events

CREDENCE trial – A new era in the treatment of Diabetic Kidney Disease in Type 2 Diabetes Mellitus

Dr Anna Strzelecka, chaired by Dr Nigel Campbell (20 minutes and a 20-minute Q&A)

This promotional video presentation was originally broadcast on 17th September 2020 at the Northern Ireland PCDS conference.
The broadcast taking place on 23rd March 2021 will include a live Q&A.

CREDENCE: Bringing the Data to Life and Implementation in Primary Care

Professor Jeff Stevens, chaired by Dr Richard Tristham (20 minutes and a 20-minute Q&A)

This promotional video presentation was originally broadcast on 6th October 2020 at the Welsh PCDS conference.
The broadcast taking place on 24th March 2021 will include a live Q&A.

CREDENCE Trial – A New Era in the Treatment of Diabetic Kidney Disease in Type 2 Diabetes Mellitus

Dr Chris Smith, chaired by Dr Lyndsey McConnell (20 minutes and a 20-minute Q&A)

This promotional video presentation was originally broadcast on 20th October 2020 at the Scottish PCDS conference.
The broadcast taking place on 31st March 2021 will include a live Q&A.

CREDENCE: A paradigm shift in the management of Diabetic Kidney Disease

Professor James Burton, chaired by Dr Amrit Lamba (20 minutes and a 20-minute Q&A)

This promotional video presentation was originally broadcast on 5th November 2020 at the National PCDS conference.
The broadcast taking place on 14th April 2021 will include a live Q&A.

Speakers

James Burton (2)

Professor James Burton

Professor of Renal Medicine, Department of Cardiovascular Sciences, University of Leicester, Leicester

Professor James Burton is Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester as well as an Honorary Consultant Nephrologist. He is a member of the UK Renal Association Clinical Guidelines Committee and has chaired a number of recent UK guideline updates, including lifestyle and physical activity in patients with kidney disease. He sits on a number of UK Kidney Research Consortium Clinical Study Groups and is a member of the UK Renal Trials Network. 

His research portfolio includes mechanisms behind the development of uraemic cardiovascular disease through to interventional clinical trials to improve patient outcomes; his clinical work with dialysis patients has been shortlisted for two NHS Innovation awards.

Nigel Campbell (2)

Dr Nigel Campbell

GP, Lisburn

Dr Nigel Campbell has been a GP in Lisburn since 1995. He has had an interest in diabetes for many years, working for a time in hospital clinics, and he continues to run his practice’s in-house diabetes clinic. He represents Northern Ireland on the committee of the Primary Care Diabetes Society and is currently treasurer of the charity.

Dr Campbell has served as Chair of South Eastern Local Commissioning Group for an 8-year period and sits on a number of diabetes-related committees. He believes strongly that primary care is the right place for the delivery of the majority of diabetes care and is keen to see that primary care teams are appropriately skilled, and resourced, to do so.

Amrit Lamba (2)

Dr Amrit Lamba

GPwSI in Diabetes and Partner at Colindale Medical Centre, London

Dr Amrit Lamba is a GP Partner at Colindale Medical Centre in Barnet CCG. Dr Lamba is also a lead clinician for the Barnet Federated GPs Diabetes Network and a board member for the Community Diabetes Service. He is a clinical cluster lead for the Barnet Federated GPs Research Network supporting local primary care participation in national research projects. In 2017, Dr Lamba founded the Barnet Diabetes Forum which hosted regular educational events and networking opportunities for primary care clinicians with an interest in diabetes.

Dr Lyndsey McConnell (2)

Dr Lyndsey McConnell

GP, Kinlochleven and GPwSI in Diabetes, Glasgow

Dr Lyndsey McConnell is a general practitioner working in Kinlochleven in the Scottish Highlands. She also works as a GPwSI in Diabetes at the Diabetes Centre at Gartnavel Hospital in Glasgow. She has completed an MSc in Diabetes and is a tutor for the post graduate diploma in Diabetes and a MSc supervisor for courses run by the University of Warwick.

Dr Chris Smith (1)

Dr Chris Smith

Consultant Physician in Diabetes and Endocrinology, Paisley

Dr Chris Smith is working at the Royal Alexandra Hospital, Paisley, as Consultant Physician in Diabetes and Endocrinology, since appointment in August 2013. He also leads the Diabetes input to the Gestational diabetes service at the Royal Alexandra Hospital and chairs the Type 2 Diabetes subgroup of the NHS Greater Glasgow & Clyde Managed Clinical Network. Dr Smith is always interested in novel therapies in Diabetes and has been involved in several regional and national studies looking at use of incretin-based therapies and SGLT2 inhibitors. He is also one of Diabetes UK’s Clinical Champions.

Prof Jeff Stephens (1)

Professor Jeff Stephens

Clinical Professor of Diabetes & Consultant Physician, Swansea University & Swansea Bay University Health Board, Swansea

Professor Jeff Stephens qualified in Medicine from Imperial College, London in 1994. He undertook specialist training in Diabetes, Endocrinology and General Internal Medicine throughout Central London. Between 2001-2004 he undertook a PhD in Genetics based at the Centre for Cardiovascular Genetics at University College London, which was supported by a Diabetes UK Clinical Training Fellowship. 

He returned to Wales in 2005 to take up the post of Senior Clinical Lecturer in Swansea University Medical School. He is currently Clinical Professor of Diabetes based at Swansea University and a Consultant Physician in Diabetes, Endocrinology and General Internal Medicine at Morriston Hospital, Swansea. He is actively involved in both teaching and research and continues as a practicing physician in diabetes, endocrinology and general medicine. 

He has held roles as Assistant Medical Director for Medical Education within ABMU Health Board and Associate Dean for Academic Careers within the Wales Deanery. He is also a member of the Diabetes UK Committee of Healthcare Professionals and Chair of the Diabetes UK Professional Conference Organising Committee for 2020 and 2021. He has over 170 peer-reviewed publications.

Anna Strzelecka (2)

Dr Anna Strzelecka

SAS Doctor in General Medicines and Endocrinology, Antrim

Dr Anna Strzelecka graduated from Queen’s University Belfast in 2003. For the last 12 years she has been working as a Speciality Doctor in General Medicine and Endocrinology. She completed her MRCP exams in 2010 and obtained a master’s degree in Diabetes through Cardiff University in 2015. She is currently working at Antrim Area Hospital and has special interest in adult diabetes and diabetes in pregnancy. Dr Strzelecka is also heavily involved in clinical research.

Dr Richard Tristham (2)

Dr Richard Tristham

GP Partner, Cwmtawe Medical Group, Swansea

Dr Richard Tristham is a GP partner with the Cwmtawe Medical Group and has a keen interest in developing new models of working, service improvement and innovation. Dr Tristham is the Clinical Director for Primary and Community Services for Cluster development, Lead Primary Care Clinician for diabetes as well as being Co-Chair for the Diabetes Planning and Delivery Group for Swansea Bay University Health Board. He combines his Health Board commitments with being a front-line GP at the Cwmtawe Medical Group in the Swansea Valley.

Book your place for our upcoming promotional webcast series

A practical guide for Primary Care:
Putting the CREDENCE data into practice for the management of Diabetic Kidney Disease (DKD) in people with T2DM

Taking place in March and April 2021

In association with

References

  1. Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302-308.
  2. Brenner B, et al. N Engl J Med. 2001;345(12):861-869.
  3. Lewis E, et al. N Engl J Med. 2001;345(12):851-860.
  4. Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.
  5. Neuen BL, et al. Lancet Diabetes and Endocrinology. 2019; 7(11): 845-854.

Adverse events should be reported. Reporting forms and further information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk

UK-INV-2100054 | March 2021

A practical guide for Primary Care: Putting the CREDENCE data into practice for the management of Diabetic Kidney Disease (DKD) in people with T2DM

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.

Adverse events should be reported. Reporting forms and further information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk

UK-INV-2100065 | March 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.